65 results about "Obstructive diseases" patented technology

Methods, apparatus, and kits for enhancing breathing in patients suffering from chronic pulmonary obstructive disease are described. The methods and apparatus rely on increasing flow resistance to expiration in a manner which mimics “pursed lip” breathing which has been found to benefit patients suffering from this disease. In a first example, a device is implanted in a trachea or bronchial passage to increase flow resistance, preferably selectively increase resistance to expiration relative to inspiration. In a second embodiment, a mouthpiece is provided, again to increase resistance to expiration, preferably with a lesser increase in flow resistance to inspiration. In a third embodiment, the patient's trachea or bronchial passage is modified by the application of energy in order to partially close the lumen therethrough.

An assessment of sleep quality and sleep disordered breathing is determined from cardiopulmonary coupling between two physiological data series. An R-R interval series is derived from an electrocardiogram (ECG) signal. The normal beats from the R-R interval series are extracted to produce a normal-to-normal interval series. The amplitude variations in the QRS complex are used to extract a surrogate respiration signal (i.e., ECG-derived respiration) associated with the NN interval series. The two series are corrected to remove outliers, and resampled. The cross-spectral power and coherence of the two resampled signals are calculated over a plurality of coherence windows. For each coherence window, the product of the coherence and cross-spectral power is used to calculate coherent cross-power. Using the appropriate thresholds for the coherent cross-power, the proportion of sleep spent in CAP, non-CAP, and wake and / or REM are determined. Coherent cross-power can be applied to differentiate obstructive from non-obstructive disease, and admixtures of the same.

An assessment of sleep quality and sleep disordered breathing is determined from cardiopulmonary coupling between two physiological data series. An R-R interval series is derived from an electrocardiogram (ECG) signal. The normal beats from the R-R interval series are extracted to produce a normal-to-normal interval series. The amplitude variations in the QRS complex are used to extract a surrogate respiration signal (i.e., ECG-derived respiration) associated with the NN interval series. The two series are corrected to remove outliers, and resampled. The cross-spectral power and coherence of the two resampled signals are calculated over a plurality of coherence windows. For each coherence window, the product of the coherence and cross-spectral power is used to calculate coherent cross-power. Using the appropriate thresholds for the coherent cross-power, the proportion of sleep spent in CAP, non-CAP, and wake and / or REM are determined. Coherent cross-power can be applied to differentiate obstructive from non-obstructive disease, and admixtures of the same.

In accordance with certain illustrative embodiments, methods and apparatuses of treating obstructive disorders of the structure of an eye or eyelid are disclosed. The treating may involve applying heat to the structure containing the obstructive disorder to melt an obstruction in the structure and place the obstruction in a melted state. The heat may be maintained for a time period to melt the obstruction and place the obstruction in the melted state. The structure may be treated by expressing the melted obstruction from the structure. The treating may be carried out either during the time period or after the time period when heat is applied but while the obstruction is in the melted state. In certain embodiments, the method further involves subsequently treating the structure by use of a pharmacological agent. This abstract is not to be considered limiting, since other embodiments may deviate from the features described in this abstract.

The invention relates to the technical field of antibody engineering and in particular discloses a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) resistant monoclonal antibody. The monoclonal antibody disclosed by the invention comprises an amino acid sequence coding an antibody variable region and a CDR region. The invention further discloses an acquiring method and application of the monoclonal antibody. The method comprises the following steps: screening a PCSK9 resistant monoclonal antibody from a phage antibody library, performing affinity maturation through a method for constructing the phage antibody library by virtue of strand displacement, performing mutant library-construction screening on light-chain CDR1, 2 and 3 regions of the monoclonal antibody obtained by preliminaryscreening, selecting a monoclonal antibody with high affinity, performing mutant library-construction screening on heavy-chain CDR1, 2 and 3 regions of the monoclonal antibody, and finally screeningthe PCSK9 resistant monoclonal antibody with high affinity. The PCSK9 resistant monoclonal antibody obtained in the invention has excellent affinity to PCSK9, is capable of inhibiting binding betweenthe PCSK9 and ligands thereof, and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombosis-obstructive diseases.

The invention relates to traditional Chinese medicine particles for treating the syndrome of insufficiency of lung and kidney qi caused by chronic obstructive disease of lung, which can effectively solve the problem of treatment medication for the syndrome of insufficiency of lung and kidney qi caused by chronic obstructive disease of lung. The traditional Chinese medicine particles are prepared from 6-12g of ginseng, 15-30g of radix astragali, 9-15g of cornel, 9-15g of wolfberry fruit, 6-12g of magnolia vine fruit, 6-12g of epimedium, 9-15g of thunberg fritillary bulb, 9-15g of red peony root, 9-15g of earthworm, 9-15g of perilla fruit, 15-30g of Japanese ardisia and 9-15g of dried orange peel. The traditional Chinese medicine particles have abundant raw materials and a scientific and advanced preparation method, have the efficacies of supplementing qi, benefiting lung and kidney, resolving phlegm and promoting blood circulation, and are innovations in the traditional Chinese medicine.

The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.